论文部分内容阅读
目的:对比观察氯吡格雷与阿斯匹林抗冠心病血小板聚集的临床疗效。方法:选取2016年1月至2016年8月东莞市横沥镇人民医院收治的84例冠心病患者,将其按照口服抗血小板药物的不同分成氯吡格雷组与阿斯匹林组各42例,对比两组患者治疗后的临床疗效。结果:阿斯匹林组的总有效率为76.2%,氯吡格雷组的总有效率为92.9%,氯吡格雷组明显高于阿斯匹林组,差异具有统计学意义(P<0.05);氯吡格雷组患者的平均血小板聚集率及平均血小板反应指数降低幅度均明显大于阿斯匹林组,差异具有统计学意义(P<0.05);阿斯匹林组的不良反应发生率为9.5%,氯吡格雷组的不良反应发生率为2.4%,氯吡格雷组明显低于阿斯匹林组,差异有统计学意义(P<0.05)。结论:口服抗血小板药物在冠心病治疗中的应用效果理想而氯吡格雷疗效优于阿司匹林。
Objective: To compare the clinical efficacy of clopidogrel and aspirin against platelet aggregation in patients with coronary heart disease. Methods: From January 2016 to August 2016, 84 patients with coronary heart disease admitted to Hengli Town People’s Hospital of Dongguan City were divided into two groups: clopidogrel group and aspirin group according to oral antiplatelet drugs, 42 cases each , Comparing the clinical efficacy of two groups of patients after treatment. Results: The total effective rate of aspirin group was 76.2%, that of clopidogrel group was 92.9%, and that of clopidogrel group was significantly higher than that of aspirin group (P <0.05) ; The average platelet aggregation rate and mean platelet reactivity index in patients with clopidogrel were significantly lower than those in aspirin group (P <0.05); the incidence of adverse reactions in aspirin group was 9.5 %. The incidence of adverse reactions in clopidogrel group was 2.4%, while that in clopidogrel group was significantly lower than that in aspirin group (P <0.05). Conclusion: The effect of oral antiplatelet drugs in the treatment of coronary heart disease is satisfactory and that of clopidogrel is better than aspirin.